Elevate your practice with the latest breakthroughs in #hematology. Discover cutting-edge data in this collection of On Location video interviews from #ASH25, including new research in #MMsm, #CLL, and more: https://ow.ly/GqII50Y8i2V
Wiley Clinical and Health
#HemeSky #MedSky
Wiley Clinical and Health
#HemeSky #MedSky
February 5, 2026 at 4:05 PM
Elevate your practice with the latest breakthroughs in #hematology. Discover cutting-edge data in this collection of On Location video interviews from #ASH25, including new research in #MMsm, #CLL, and more: https://ow.ly/GqII50Y8i2V
Wiley Clinical and Health
#HemeSky #MedSky
Wiley Clinical and Health
#HemeSky #MedSky
"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.
https://bit.ly/4t4hyN6
#ASH25
https://bit.ly/4t4hyN6
#ASH25
Significant Barriers to Health Literacy Exist for Patients With Thalassemia
Researchers determined there may be overestimation of disease understanding and barriers to health literacy among patients with thalassemia.
bit.ly
January 27, 2026 at 8:35 PM
"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.
https://bit.ly/4t4hyN6
#ASH25
https://bit.ly/4t4hyN6
#ASH25
The ASH25 Lymphoma Roundup Episode is Out - Edward Cliff
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Edward Cliff: The ASH25 Lymphoma Roundup Episode is Out - OncoDaily
Edward Cliff: The ASH25 Lymphoma Roundup Episode is Out / ASH25, cancer, Eddie Cliff, Edward Cliff, lymphoma, OncoDaily, Oncology
oncodaily.com
January 26, 2026 at 12:50 AM
The ASH25 Lymphoma Roundup Episode is Out - Edward Cliff
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
From conference data to clinical impact. Amir T. Fathi, MD shares key leukemia takeaways from American Society of Hematology 2025, highlighting what new data may mean for patients with AML and CML.
🎧 Listen to the full discussion:https://bit.ly/3NN1bUW
#ASH25 #MedicalEducation
🎧 Listen to the full discussion:https://bit.ly/3NN1bUW
#ASH25 #MedicalEducation
January 23, 2026 at 8:48 PM
From conference data to clinical impact. Amir T. Fathi, MD shares key leukemia takeaways from American Society of Hematology 2025, highlighting what new data may mean for patients with AML and CML.
🎧 Listen to the full discussion:https://bit.ly/3NN1bUW
#ASH25 #MedicalEducation
🎧 Listen to the full discussion:https://bit.ly/3NN1bUW
#ASH25 #MedicalEducation
Take the first step toward building regional partnerships at Highlights of ASH in the Mediterranean, Middle East, and North Africa! 🌍
Connect with #hematology experts as you explore the clinical application of new #ASH25 evidence: https://ow.ly/liNC50Y0G1w #Hemesky #Medsky
Connect with #hematology experts as you explore the clinical application of new #ASH25 evidence: https://ow.ly/liNC50Y0G1w #Hemesky #Medsky
January 21, 2026 at 10:05 PM
Take the first step toward building regional partnerships at Highlights of ASH in the Mediterranean, Middle East, and North Africa! 🌍
Connect with #hematology experts as you explore the clinical application of new #ASH25 evidence: https://ow.ly/liNC50Y0G1w #Hemesky #Medsky
Connect with #hematology experts as you explore the clinical application of new #ASH25 evidence: https://ow.ly/liNC50Y0G1w #Hemesky #Medsky
The January issue is out now! Issue highlights include meeting coverage and reports from #ASH25, a feature on #patient support programs, updates on international guidelines for #pediatric #AcuteMyeloidLeukemia #AML, and more. See the full lineup here: https://ow.ly/tgpq50Y0C89
January 21, 2026 at 2:55 PM
The January issue is out now! Issue highlights include meeting coverage and reports from #ASH25, a feature on #patient support programs, updates on international guidelines for #pediatric #AcuteMyeloidLeukemia #AML, and more. See the full lineup here: https://ow.ly/tgpq50Y0C89
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.
https://bit.ly/45HWHVP
#ASH2025 #lymsm
https://bit.ly/45HWHVP
#ASH2025 #lymsm
BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL - Hematology Advisor
Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting.
bit.ly
January 20, 2026 at 5:48 PM
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.
https://bit.ly/45HWHVP
#ASH2025 #lymsm
https://bit.ly/45HWHVP
#ASH2025 #lymsm
CAR T-cell therapy works. Recovery is the challenge.
New research shows a stem cell boost may help restore blood counts faster after CAR T-cell treatment. Learn more from IMF Scientific Advisory Board experts:
https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
New research shows a stem cell boost may help restore blood counts faster after CAR T-cell treatment. Learn more from IMF Scientific Advisory Board experts:
https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
January 17, 2026 at 2:45 PM
CAR T-cell therapy works. Recovery is the challenge.
New research shows a stem cell boost may help restore blood counts faster after CAR T-cell treatment. Learn more from IMF Scientific Advisory Board experts:
https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
New research shows a stem cell boost may help restore blood counts faster after CAR T-cell treatment. Learn more from IMF Scientific Advisory Board experts:
https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
Join Dr. Baljevic and Me for an Educational Meeting on ASH25 and SABCS25 Advances - Erika Hamilton
@erikahamilton9.bsky.social
oncodaily.com/voices/erika...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@erikahamilton9.bsky.social
oncodaily.com/voices/erika...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Erika Hamilton: Join Dr. Baljevic and Me for an Educational Meeting on ASH25 and SABCS25 Advances - OncoDaily
Erika Hamilton: Join Dr. Baljevic and Me for an Educational Meeting on ASH25 and SABCS25 Advances / ASH25, cancer, Erika Hamilton, Muhamed Baljevic,
oncodaily.com
January 17, 2026 at 12:39 AM
Join Dr. Baljevic and Me for an Educational Meeting on ASH25 and SABCS25 Advances - Erika Hamilton
@erikahamilton9.bsky.social
oncodaily.com/voices/erika...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@erikahamilton9.bsky.social
oncodaily.com/voices/erika...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Advance your career with world-class ASH content in Kuala Lumpur! 🧠
At Highlights of ASH in Asia-Pacific, ASH and the Malaysian Society of Haematology will bring leading #hematology experts and breakthrough #ASH25 research to you.
Secure your spot: https://ow.ly/zX9O50XXik9 #Hemesky #Medsky
At Highlights of ASH in Asia-Pacific, ASH and the Malaysian Society of Haematology will bring leading #hematology experts and breakthrough #ASH25 research to you.
Secure your spot: https://ow.ly/zX9O50XXik9 #Hemesky #Medsky
January 16, 2026 at 1:01 AM
Advance your career with world-class ASH content in Kuala Lumpur! 🧠
At Highlights of ASH in Asia-Pacific, ASH and the Malaysian Society of Haematology will bring leading #hematology experts and breakthrough #ASH25 research to you.
Secure your spot: https://ow.ly/zX9O50XXik9 #Hemesky #Medsky
At Highlights of ASH in Asia-Pacific, ASH and the Malaysian Society of Haematology will bring leading #hematology experts and breakthrough #ASH25 research to you.
Secure your spot: https://ow.ly/zX9O50XXik9 #Hemesky #Medsky
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/nemtabr...
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL | OncLive
Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
www.onclive.com
January 15, 2026 at 7:22 PM
Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/nemtabr...
Investigators from the Alliance for Clinical Trials in Oncology presented six abstracts advancing treatments for leukemia, lymphoma and myeloma at the 67th Annual Meeting of the American Society Hematology (#ASH25) held last month. https://bit.ly/2025ASH
January 15, 2026 at 5:00 PM
Investigators from the Alliance for Clinical Trials in Oncology presented six abstracts advancing treatments for leukemia, lymphoma and myeloma at the 67th Annual Meeting of the American Society Hematology (#ASH25) held last month. https://bit.ly/2025ASH
For those facing extramedullary myeloma, new research offers real hope. Studies show that combining two immune therapies may improve outcomes, even in advanced disease. Learn more from IMF experts: https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
#IMFSAB #IMFASH25 #ASH25
January 14, 2026 at 8:59 PM
For those facing extramedullary myeloma, new research offers real hope. Studies show that combining two immune therapies may improve outcomes, even in advanced disease. Learn more from IMF experts: https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25
#IMFSAB #IMFASH25 #ASH25
Explore all of the abstracts from our 67th Annual Meeting and see what's driving the field of hematology forward today: ashpublications.org/blood/issue/... #ASH25 #Abstracts
January 12, 2026 at 9:14 PM
Explore all of the abstracts from our 67th Annual Meeting and see what's driving the field of hematology forward today: ashpublications.org/blood/issue/... #ASH25 #Abstracts
New IMF research shows that acting early in smoldering myeloma may help stop cancer before it starts. Results from the GEM-CESAR study highlight how early treatment and close monitoring can protect patients and quality of life. https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25 #IMFBSRI
#IMFSAB #IMFASH25 #ASH25 #IMFBSRI
January 12, 2026 at 4:19 PM
New IMF research shows that acting early in smoldering myeloma may help stop cancer before it starts. Results from the GEM-CESAR study highlight how early treatment and close monitoring can protect patients and quality of life. https://mmsm.link/4boNwxd
#IMFSAB #IMFASH25 #ASH25 #IMFBSRI
#IMFSAB #IMFASH25 #ASH25 #IMFBSRI
New data📝Phase II preliminary results, presented by Anita Kumar at #ASH25, show the BOVen triplet combination achieved a 98% metabolic response rate in older patients with MCL, with a 2-year PFS of 86% and OS of 92%.
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/B8pRi7c
#lymphoma #lymsm #MedNews #MedEd
January 12, 2026 at 10:30 AM
Résumés de #Breakthrough 👑 #Myelome 🩸 : le Conseil consultatif scientifique du FMI et les membres du Groupe de travail international sur le #MyélomeMultiple 🩸 occupent le devant de la scène à l’ #ASH25
www.myeloma.org/blog/breakth...
www.myeloma.org/blog/breakth...
Breakthrough Myeloma Abstracts: IMF Scientific Advisory Board and International Myeloma Working Group Members Take Center Stage at ASH 2025
The IMF takes you to the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, where members of the IMF SAB and IMWG presented breakthrough abstracts in myeloma research.
www.myeloma.org
January 10, 2026 at 11:25 AM
Résumés de #Breakthrough 👑 #Myelome 🩸 : le Conseil consultatif scientifique du FMI et les membres du Groupe de travail international sur le #MyélomeMultiple 🩸 occupent le devant de la scène à l’ #ASH25
www.myeloma.org/blog/breakth...
www.myeloma.org/blog/breakth...
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25, from @hematologyadvisor.bsky.social.
https://bit.ly/49lkOdZ
#lymsm
https://bit.ly/49lkOdZ
#lymsm
BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL
Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination therapy may be a new standard treatment option for patie...
bit.ly
January 9, 2026 at 9:08 PM
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25, from @hematologyadvisor.bsky.social.
https://bit.ly/49lkOdZ
#lymsm
https://bit.ly/49lkOdZ
#lymsm
The top 10 most impactful myeloma breakthroughs in CAR T-cell therapy and bispecific antibodies from ASH. Watch now: https://mmsm.link/4qeZrlU
#ASH25 #IMFASH25 #ASKTHEIMF
#ASH25 #IMFASH25 #ASKTHEIMF
January 9, 2026 at 7:28 PM
The top 10 most impactful myeloma breakthroughs in CAR T-cell therapy and bispecific antibodies from ASH. Watch now: https://mmsm.link/4qeZrlU
#ASH25 #IMFASH25 #ASKTHEIMF
#ASH25 #IMFASH25 #ASKTHEIMF
Test your knowledge and earn CME credit! If you don’t already have it, now is the perfect time to get our Hematology 2025 ASH Education Program. Digital access is FREE for members and #ASH25 attendees. Anyone can purchase digital and/or print editions here apps.hematology.org/store/produc...
January 9, 2026 at 3:56 PM
Test your knowledge and earn CME credit! If you don’t already have it, now is the perfect time to get our Hematology 2025 ASH Education Program. Digital access is FREE for members and #ASH25 attendees. Anyone can purchase digital and/or print editions here apps.hematology.org/store/produc...
See what's to come in this month's issue! Editor-in-Chief Bethany Samuelson Bannow, MD, MCR (she/her) shares what readers can expect, including coverage from #ASH25, a feature on #patient assistance programs, a challenging case of refractory #Hodgkin #lymphoma, and more: https://ow.ly/Bnww50XT7Uw
January 9, 2026 at 2:05 PM
See what's to come in this month's issue! Editor-in-Chief Bethany Samuelson Bannow, MD, MCR (she/her) shares what readers can expect, including coverage from #ASH25, a feature on #patient assistance programs, a challenging case of refractory #Hodgkin #lymphoma, and more: https://ow.ly/Bnww50XT7Uw
Éti-cel dans le #Lymphome non-hodgkinien ( #LNH 🩸) R/R #NATHALI_01
S'appuyant sur les données préliminaires de phase 1 présentées lors du congrès annuel de l' #ASH25, #Cellectis se concentre sur la maximisation de l'impact clinique de son produit candidat à double #CAR_Tcell 🧬
S'appuyant sur les données préliminaires de phase 1 présentées lors du congrès annuel de l' #ASH25, #Cellectis se concentre sur la maximisation de l'impact clinique de son produit candidat à double #CAR_Tcell 🧬
January 9, 2026 at 6:21 AM
Éti-cel dans le #Lymphome non-hodgkinien ( #LNH 🩸) R/R #NATHALI_01
S'appuyant sur les données préliminaires de phase 1 présentées lors du congrès annuel de l' #ASH25, #Cellectis se concentre sur la maximisation de l'impact clinique de son produit candidat à double #CAR_Tcell 🧬
S'appuyant sur les données préliminaires de phase 1 présentées lors du congrès annuel de l' #ASH25, #Cellectis se concentre sur la maximisation de l'impact clinique de son produit candidat à double #CAR_Tcell 🧬
From #ASH25: We break down the 10 most impactful myeloma breakthroughs, including advances in CAR T-cell therapy and bispecific antibodies and what this latest research means for people living with myeloma. Watch now: mmsm.link/4qeZrlU
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
January 8, 2026 at 11:28 PM
From #ASH25: We break down the 10 most impactful myeloma breakthroughs, including advances in CAR T-cell therapy and bispecific antibodies and what this latest research means for people living with myeloma. Watch now: mmsm.link/4qeZrlU
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
#IMFASH25 #ASKTHEIMF
@jmikhaelmd.bsky.social
How are new strategies improving prevention and treatment of #GVHD after HCT?
Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd
🔗 bit.ly/4apt6Un
Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd
🔗 bit.ly/4apt6Un
MDADI
MDADI
bit.ly
January 8, 2026 at 5:32 PM
How are new strategies improving prevention and treatment of #GVHD after HCT?
Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd
🔗 bit.ly/4apt6Un
Watch this on-demand activity featuring insights from @DrZackDeFilipp, @hamiltkyb & Dr. Amandeep Salhotra—produced with @peerview.bsky.social #ASH25 #MedEd
🔗 bit.ly/4apt6Un